More PYC Therapeutics Limited news
PYC Therapeutics LimitedASX: PYC

Presentation of Clinical Proof of Concept in Lead Program

Apr 27, 2025 at 11:23 PM EDT · Issued by PYC Therapeutics Limited

Filed with ASX · Apr 27, 2025 at 11:23 PM EDT · 9 pages · English

On 6ix: 6ix.com/news/presentation-of-clinical-proof-of-concept-in-lead-program

PYC Therapeutics Limited on 6ix

Earlier from PYC Therapeutics

  • Completion of Entitlement OfferApr 16, 2025
  • First Subject Dosed in PKD Clinical TrialApr 9, 2025
  • Placement of ShortfallApr 9, 2025
  • Retail Entitlement Offer BookletFeb 24, 2025
  • Completion of Institutional Entitlement OfferFeb 18, 2025

Later from PYC Therapeutics

  • Approval to Escalate Dosing in Kidney Disease TrialMay 25, 2025
  • SRC Approves Dose Escalation in ADOA Clinical TrialJun 10, 2025
  • FDA Alignment on Registrational Trial Design RP11 ProgramJun 22, 2025
  • Fourth Drug Program Progressing to Human TrialsJun 26, 2025
  • Approval to Progress Kidney Disease Trial to Next StageJul 6, 2025
All PYC Therapeutics news releases↗

Follow PYC Therapeutics into a list and get an email when it puts out news.

Follow PYC Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer